Vector holding clinical trials to boost immunity with 3 shots of EpiVacCorona vaccine - developer
MOSCOW. May 5 (Interfax) - The Vector Center of the Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor) is testing the possibility of administering three shots of the EpiVacCorona coronavirus vaccine as a way to enhance the effect of antibodies, head of the Vector department for zoonotic infections Alexander Ryzhikov said. We have tested this, the triple vaccination, on animals [.] and the effect of higher and longer immunity has been confirmed; phases 1-2 of the clinical trials, in which three shots of the vaccine are administered, are underway, Ryzhikov said on Rospotrebnadzor s Instagram account.
Russian Coronavirus Vaccine Maker Studying 3rd Booster Shot May 5, 2021 A man receives an injection of the EpiVacCorona vaccine against Covid-19 at municipal polyclinic in St. Petersburg. Peter Kovalev / TASS
The makers of Russia’s second approved coronavirus vaccine EpiVacCorona are studying third doses to boost recipients immune response, a senior scientist said Wednesday.
Approved last fall and added to Russia’s mass immunization program last month, EpiVacCorona has come under scrutiny after a group of late-trial study participants claimed that it does not produce an immune response. Early-trial results published in a Russian medical journal this spring disputed that claim, saying that all adults involved in phase one and two trials had developed antibodies.